Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

8.530 +0.280 (+3.39%)
Streaming Delayed Price Updated: 2:47 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Why Shares of Keros Therapeutics Jumped This Week ↗
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
News headline image
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments ↗
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
News headline image
7 Thrilling Biotech Stocks for Aggressive Investors to Buy ↗
Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. 
Via InvestorPlace
News headline image
What 8 Analyst Ratings Have To Say About Vir Biotechnology ↗
 
Via Benzinga
News headline image
Where Vir Biotechnology Stands With Analysts ↗
 
Via Benzinga
News headline image
Vir Biotechnology's Earnings Outlook ↗
 
Via Benzinga
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗
 
Via Benzinga
News headline image
Biotech Stocks And The SVB Collapse — Here's What We Know ↗
The collapse of SVB will have a big impact on early-stage, venture-backed companies. 
Via Investor's Business Daily
News headline image
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023 ↗
 
Via Benzinga
News headline image
Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results ↗
Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results. Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s... 
Via Benzinga
News headline image
The Top 7 Growth Stocks in Biotech ↗
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
News headline image
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
News headline image
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab 
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
News headline image
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗
 
Via Benzinga
News headline image
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
News headline image
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
News headline image
Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.